PharmEasy’s Costly Thyrocare Gamble Unravels as High-Interest Debt Catches Up
PharmEasy’s ambitious ₹4,546-crore acquisition of Thyrocare in 2021, once celebrated as a defining moment for India’s digital health sector, has now turned into a case…
December 2








